122 related articles for article (PubMed ID: 38465588)
1. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent
Liu L; Zhang H; Hou J; Zhang Y; Wang L; Wang S; Yao Z; Xie T; Wen X; Xu Q; Dai L; Feng Z; Zhang P; Wu Y; Sun H; Liu J; Yuan H
J Med Chem; 2024 Mar; 67(6):4977-4997. PubMed ID: 38465588
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy.
Xu Y; Du H; Guo W; Liu B; Yan W; Zhang C; Qin L; Huang J; Wang H; Wu S; Ren W; Zou Y; Wang J; Zhu Q; Xu Y; Gu H
J Med Chem; 2024 Mar; 67(5):4083-4099. PubMed ID: 38348878
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W
Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636
[TBL] [Abstract][Full Text] [Related]
4. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction.
Wang F; Ye W; He Y; Zhong H; Zhu Y; Han J; Gong X; Tian Y; Wang Y; Wang S; Ji S; Liu H; Yao X
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835382
[TBL] [Abstract][Full Text] [Related]
5. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
[TBL] [Abstract][Full Text] [Related]
6. Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice.
Li N; Tang J; Yang J; Zhu B; Wang X; Luo Y; Yang H; Jang F; Zou J; Liu Z; Wang Z
Cancer Lett; 2021 Feb; 498():121-129. PubMed ID: 33129956
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
8. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
9. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
10. Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models.
Franks SE; Fabian KP; Santiago-Sánchez G; Wolfson B; Hodge JW
Oncoimmunology; 2022; 11(1):2124666. PubMed ID: 36211806
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
12. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
14. COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes.
Cecil DL; Gad EA; Corulli LR; Drovetto N; Lubet RA; Disis ML
Cancer Prev Res (Phila); 2022 Apr; 15(4):225-231. PubMed ID: 34987061
[TBL] [Abstract][Full Text] [Related]
15. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.
Lee EJ; Kim YS; Kim JH; Woo KW; Park YH; Ha JH; Li W; Kim TI; An BK; Cho HW; Han JH; Choi JG; Chung HS
Phytomedicine; 2024 Mar; 125():155370. PubMed ID: 38266440
[TBL] [Abstract][Full Text] [Related]
16. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
Fujiwara K; Shigematsu K; Tachibana M; Okada N
IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
[TBL] [Abstract][Full Text] [Related]
17. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
19. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract][Full Text] [Related]
20. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]